RVPNs decorated with a composite of an anti-EGFR single-domain antibody and iRGD provided long circulation time, improved extravasation and tumor localization, enhanced parenchymal penetration, as well as increased interaction with the overexpressed EGFR receptors [126]. This evidence concerns the gene EGFR and neoplasm.